Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Srikanth Nagalla, MBBS,MS, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 1071.

https://doi.org/10.1182/blood-2019-130963

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Won Seog Kim, Michinori Ogura, Christian Buske, Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Yuriy Vinnyk, Panagiotis Tsirigotis, Piera Viero, Elena Volodicheva, Samuel Fourie, Juan Soler

Blood (2015) 126 (23): 5111.

https://doi.org/10.1182/blood.V126.23.5111.5111

Published: 2015

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Alessandro M. Vannucchi, MD, Heinz Gisslinger, MD, Claire N. Harrison, Haifa Kathrin Al-Ali, MD, Ester Pungolino, MD, Jean-Jacques Kiladjian, MD PhD, Francoise Boyer-Perrard, MD, Franck E. Nicolini, MD PhD, Shuyuan Mo, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Peter A. te Boekhorst

Blood (2015) 126 (23): 2817.

https://doi.org/10.1182/blood.V126.23.2817.2817

Published: 2015

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 178.

https://doi.org/10.1182/blood.V120.21.178.178

Published: 2012

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 801.

https://doi.org/10.1182/blood.V120.21.801.801

Published: 2012

Journal Articles

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Vikas Gupta, MD, FRCP, FRCPath, Andrew W Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Mark R. Litzow, MD, William J Hogan, MBBCh, Kebede Begna, MD, Gregg Smith, PhD, MBA, Linda M Bavisotto, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3849.

https://doi.org/10.1182/blood.V118.21.3849.3849

Published: 2011

Journal Articles

Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Andreas Hochhaus, MD, Gert Ossenkoppele, MD, PhD, Josy Reiffers, MD, Ming Yao, MD, Hirohiko Shibayama, MD, PhD, Norbert Gattermann, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, MD, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Clarisse Lobo, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 114.

https://doi.org/10.1182/blood.V118.21.114.114

Published: 2011

Journal Articles

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Elliott Vichinsky, MD, Francoise Bernaudin, MD, Gian Luca Forni, MD, Renee Gardner, MD, Kathryn Hassell, MD, Matthew M. Heeney, MD, Baba Inusa, MD, Abdullah Kutlar, MD, Peter A. Lane, MD, Liesl Mathias, MD, John B. Porter, MD, Cameron K Tebbi, MD, Felicia L. Wilson, MD, Louis Griffel, MD, Wei Deng, PhD, Vanessa Giannone, BSN, Thomas D. Coates, MD

Blood (2010) 116 (21): 845.

https://doi.org/10.1182/blood.V116.21.845.845

Published: 2010

Journal Articles

Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (Exjade®) Monotherapy in Chronically Transfused β-Thalassemia (β-Thal) Patients: 18- and 24-Month Data.

John C. Wood, Alexis A. Thompson, Carole Paley, Tara Glynos, Barinder Kang, Patricia J. Giardina, Paul R. Harmatz, Thomas Coates

Blood (2009) 114 (22): 4069.

https://doi.org/10.1182/blood.V114.22.4069.4069

Published: 2009

Journal Articles

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Pradyumna D. Phatak, Pierre Brissot, Herbert Bonkovsky, Mark Wurster, Lawrie Powell, Claus Niederau, Paul Adams, Wolfgang Stremmel, Louis Griffel, Nicola Lynch, Oliver Schoenborn-Kellenberger, Antonello Pietrangelo

Blood (2009) 114 (22): 1514.

https://doi.org/10.1182/blood.V114.22.1514.1514

Published: 2009

Journal Articles

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Ali Taher, Amal El-Beshlawy, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Blood (2008) 112 (11): 5409.

https://doi.org/10.1182/blood.V112.11.5409.5409

Published: 2008

NARROW

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (Exjade®) Monotherapy in Chronically Transfused β-Thalassemia (β-Thal) Patients: 18- and 24-Month Data.

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only